?????? ??????? ??????? ??????????????????? ? ???????????? ?? ??????? ????? ? ????-?????? ????????????? ?????? ? ????????? ? ?? 2 ????

Defect in the function of pancreatic cells is one key pathophysiological factors type 2 diabetes, particular, an imbalance between secretion insulin and glucagon, as well a decrease efficiency converting proinsulin into insulin, often observed. The aim work was to compare characteristics secretory alpha beta 43 patients with decompensated diabetes mellitus when using new classes anti-diabetic drugs: glucagon-like peptide receptors agonists (GLP1ra) inhibitors sodium-glucose transporter-2 (SGLT2i). Long-term treatment these drugs (for 12 months) contributed normalization HbA1c level % visceral fat, glucagon compared baseline level. In both groups patients, subgroups high low levels have been identified. Under influence GLP1ra therapy, subgroup, serum concentration C-peptide significantly decreased, indicating possible reduce adaptive release result glycemia decrease. Among treated SGLT-2i, pre-treatment associated higher concentrations comparing subgroup. After months treatment, no significant changes were observed SGLT2i.